Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Single Dose, Two-way, Crossover, Oral Bioequivalence Study of Lamotrigine Tablets 200 mg With Lamictal® Tablets 200 mg in Healthy, Volunteers Under Fasting Condition.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01513720

Enrollment

Registered

2012-01-20

Start date

2002-12-31

Completion date

2002-12-31

Last updated

2012-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Bioequivalence, Lamotrigine, crossover

Brief summary

This is an single dose,two-way, crossover, oral bioequivalence study.

Detailed description

The study was an single dose, two-way crossover, oral bioequivalence study of Lamotrigine tablets 200 mg of Dr. Reddy's Laboratories Limited, India comparing with that of LAMICTAL® tablets 200 mg of GlaxoSmithKline Inc, in healthy, adult, human subjects under fasting condition. 26 subjects (19 men and 7 womens) are enrolled and completed the study. The washout period is 14 days between the two periods of the study.

Interventions

DRUGLamotrigine

Lamotrigine Tablets 200 mg

DRUGLamictal®

Lamictal® 200 mg Tablets

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 44 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy males and females at least 18 years of age inclusive 2. Informed of the nature of the study and given written informed consent 3. Have a body weight within 15% of the appropriate range as defined in the 1983 Metropolitan Life Company tables and weighing at least 100 lbs.

Exclusion criteria

1. Hypersensitivity to Lamotrigine (Lamictal®) or similar compounds 2. Any history of a clinical condition which might affect drug absorption, metabolism or excretion 3. Recent history of mental illness, drug addition,drug abuse or alcoholism 4. Donation of greater than 500 ml of blood in the past 4 weeks prior to study dosing of difficulty in donating blood. 5. Received an investigational drug within the 4 weeks prior to study dosing. 6. Currently taking any prescription medication, except oral contraceptives, within the 7 days prior to study dosing or over-the -counter medication within 3 days of study dosing. This prohibition does not include vitamins or herbal preparations taken as nutritional supplements for non-therapeutics indications as judged by the attending physician. 7. Tobacco use (\>5 cigarettes per day) in the 3 months prior to study dosing. 8. If female, the subjects is lactating or has a positive pregnancy test screening and prior to each of the two treatments periods. Females of child bearing potential must use a medical acceptable method of contraception throughout the entire study period and for one week after the study is completed. Medically acceptable methods or contraception that may be used by the subject and/or her partner are; oral contraceptives, progestin injection or implants, condom with spermicide, diaphragm with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence. Females taking oral contraceptives must have taken them consistently for at least three months prior to receiving study medication.

Design outcomes

Primary

Measure	Time frame
Area under curve (AUC)	Pre-dose 0.5,1,1.5,2,2.5,3,3.5,4,5,6,8,12,24,36,48,72,96,120 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026